CAVERJECT STERILE POWDER 20 MCG — DIN 02215756
ALPROSTADIL : 20 MCG · PFIZER CANADA ULC · LIQUID ; KIT ; POWDER FOR SOLUTION · wholesale supply in Canada
Health Canada status: MARKETED
What is CAVERJECT STERILE POWDER?
CAVERJECT STERILE POWDER 20 MCG contains ALPROSTADIL : 20 MCG. It is listed in the Health Canada Drug Product Database under DIN 02215756, held by PFIZER CANADA ULC, supplied as LIQUID ; KIT ; POWDER FOR SOLUTION for INTRACAVERNOSAL administration. Health Canada currently lists it as marketed, status dated 09-Nov-2005. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is CAVERJECT STERILE POWDER used for?
CAVERJECT STERILE POWDER (alprostadil) is indicated for: the intracavernosal treatment of erectile dysfunction due to neurogenic, vasculogenic, psychogenic, or mixed etiology. Intracavernosal CAVERJECT STERILE POWDER may also be useful as an adjunct to diagnostic tests in the diagnosis of erectile dysfunction.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Alprostadil cost around the world?
Alprostadil is listed on 15 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Bahrain publishes a retail (max); Brazil publishes a preco fabrica (ex-factory ceiling). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Norway | max AUP (pharmacy retail) | 3 | 7 | NOK███.██ |
| Spain | PVP con IVA (public price) | 6 | 6 | EUR███.██ |
| Greece | producer price (ex-factory) | 3 | 3 | EUR███.██ |
| Italy | ex-factory (classe H) | 3 | 3 | EUR███.██ |
| Romania | max producer price | 3 | 3 | RON███.██ |
| Saudi Arabia | public | 3 | 3 | SAR███.██ |
| Slovakia | categorised final price | 3 | 3 | EUR███.██ |
| Australia | ex-manufacturer | 1 | 2 | AUD███.██ |
| Brazil | preco fabrica (ex-factory ceiling) | 1 | 2 | BRL███.██ |
| Hungary | producer price (ex-factory) | 2 | 2 | HUF███.██ |
| Morocco | PPV (public price) | 1 | 2 | MAD███.██ |
| South Africa | single exit price | 2 | 2 | ZAR███.██ |
| United Arab Emirates | public | 1 | 1 | AED███.██ |
| Bahrain | retail (max) | 1 | 1 | BHD███.██ |
| Iceland | max wholesale | 1 | 1 | ISK███.██ |
| Italy | prezzo al pubblico (classe A) | 1 | 1 | EUR███.██ |
42 pack listings across 35 brand entries and 14 price bases, refreshed 08 Sep 2026. Ranges span every Alprostadil pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Alprostadil in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
4 holders have a Canadian DIN containing Alprostadil, across 10 DINs, of which 2 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| PFIZER CANADA ULC | 4 | 2 | CAVERJECT STERILE POWDER, CAVERJECT STERILE POWDER - KIT 11.9MCG /VIAL, CAVERJECT STERILE POWDER - PWS 11.9MCG/VIAL, CAVERJECT STERILE POWDER - PWS 23.2MCG/VIAL | Sourceable in Canada |
| ENDO OPERATIONS LTD. | 3 | 0 | MUSE | No marketed DIN |
| BGP PHARMA ULC | 2 | 0 | VITAROS | No marketed DIN |
| PALADIN PHARMA INC. | 1 | 0 | MUSE | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 20 MCG |
|---|---|
| Dosage form | LIQUID ; KIT ; POWDER FOR SOLUTION |
| Route | INTRACAVERNOSAL |
| Pack configuration (monograph) | CAVERJECT STERILE POWDER is available in cartons containing 5 cases. Each case contains: a single dose vial of 20 mcg CAVERJECT STERILE POWDER sterile powder, 1 mL pre-filled syringe of BWFI diluent, a 27-gauge, 0.5-inch needle, 2 alcohol swabs and Patient Administration Leaflet. These cases are fitted with a lock designed for safe and convenient disposal of the contents after use. |
| Storage | Unreconstituted lyophilized sterile powder (20 mcg vials) should be stored between 2°C to 30°C. Do not freeze. Once reconstituted, the alprostadil solution must be used immediately. Do not freeze the reconstituted solution. A solution which appears cloudy, coloured or contains particles should be discarded. Do not use the vials after the expiry date listed on the label. Keep out of reach and sight of children. |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation, because this listing covers more than one of them.
Substance and classification
| Active substance | Alprostadil |
|---|---|
| ATC code | G04BE01 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02215756 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2215756 |
| Brand name | CAVERJECT STERILE POWDER |
| Generic / active ingredient | ALPROSTADIL : 20 MCG |
| Market authorization holder | PFIZER CANADA ULC |
| Health Canada schedule | Prescription |
| ATC code | G04BE01 |
| ATC anatomical main group | G — Genito-urinary system and sex hormones |
| ATC therapeutic subgroup | G04BE |
| Current status | MARKETED |
| Status date | 09-Nov-2005 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
The dose should be titrated on an individual basis by the physician, and the lowest effective dose always employed as the therapeutic dose. An effective dose is defined as one which produces an erection sufficient for intercourse with an erection duration not exceeding 1 hour. Initial Titration in Physician's Office: - Erectile Dysfunction of Vasculogenic, Psychogenic or Mixed Etiology: Initiate at 2.5 mcg of alprostadil. If partial response, increase by 2.5 mcg to 5 mcg, then in increments of 5 to 10 mcg. If no response to initial 2.5 mcg, increase to 7.5 mcg, followed by increments of 5 to 10 mcg. Patient must remain in physician's office until complete detumescence. No more than two doses within 24 hours. At least 24 hours between doses if response. - Erectile Dysfunction of Pure Neurogenic Etiology: Initiate at 1.25 mcg of alprostadil. Increase by 1.25 mcg to 2.5 mcg, then by 2.5 mcg to 5 mcg, then in 5 mcg increments. Patient must remain in physician's office until complete detumescence. No more than two doses within 24 hours. At least 24 hours between doses if response. Maintenance Therapy: - Initial injection by a medically trained health care professional. Patient (or partner) must demonstrate skill and competence with injection procedure and sterile technique before self-injection program. - The correct dose is the lowest effective dose. Reduce dose if erection persists for longer than 1 hour. Consult physician for any dose adjustments. - Regular follow-up visits, at least every 3 months, are recommended. Maximum Recommended Dose Limits: - Daily dose should not exceed 60 mcg. - NOT more than once daily and NOT more than 3 times weekly, with at least 24 hours between each dose. - Do not inject CAVERJECT STERILE POWDER into an erect penis. Administration: - Administered by direct intracavernosal injection using a 1/2-inch 27- to 30 gauge needle. - Injected into either of two corpora cavernosum along the dorso-lateral aspects of the proximal third of the penis. Avoid visible veins. Change injection site each time (alternate sides of penis and change point of injection). Cleanse injection site with alcohol swab.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
CAVERJECT STERILE POWDER (alprostadil) is contraindicated in the following individuals: - Patients who are hypersensitive to this drug or to any ingredient in the formulation, including any non-medicinal ingredient, or component of the container. - Patients who have any condition that may predispose them to priapism such as sickle cell anemia or trait, multiple myeloma or leukemia. - Patients with anatomical deformations of the penis, such as angulation, cavernosal fibrosis, Peyronie's disease. - Patients with penile implants. - Should not be used in women or children and is not for use in newborns. - Should not be used in men for whom sexual activity is inadvisable or contraindicated.
Warnings and precautions
Prolonged erection (4 to 6 hours) and/or priapism (>6 hours) are known to occur following intracavernosal administration of vasoactive substances, including CAVERJECT STERILE POWDER (alprostadil). In clinical studies, prolonged erection occurred in 4% of patients and 0.4% experienced priapism. The patient should be instructed to immediately report to his physician, or if unavailable, to seek immediate medical assistance for an erection persisting more than 3 hours. Treatment of prolonged erection/priapism should be according to established medical practice. If priapism is not treated immediately, penile tissue damage and permanent loss of potency may result. To minimize the chances of prolonged erection or priapism, CAVERJECT STERILE POWDER should be titrated slowly to the lowest effective dose. Patients on anticoagulants such as warfarin or heparin may have an increased propensity for bleeding after intracavernosal injection. An injection of CAVERJECT STERILE POWDER can induce a small amount of bleeding at the injection site. In patients infected with blood-borne diseases, this may increase the transmission of blood-borne diseases between partners. The diluent that is used to reconstitute CAVERJECT STERILE POWDER contains benzyl alcohol, a preservative that has been associated with serious adverse events, including the “gasping syndrome", and death in pediatric patients. The minimum amount of benzyl alcohol at which toxicity may occur is not known. The risk of benzyl alcohol toxicity depends on the quantity administered and the liver and kidneys' capacity to detoxify the chemical. Premature and low-birth weight infants may be more likely to develop toxicity. Benzyl alcohol can cross the placenta.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
2 of 10 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| CAVERJECT STERILE POWDER - PWS 23.2MCG/VIAL | 20 MCG | POWDER FOR SOLUTION | PFIZER CANADA ULC | MARKETED | 02215187 |
| CAVERJECT STERILE POWDER - KIT 11.9MCG /VIAL | 99.1 % | POWDER FOR SOLUTION ; KIT ; LIQUID | PFIZER CANADA ULC | CANCELLED POST MARKET | 02215748 |
| CAVERJECT STERILE POWDER - PWS 11.9MCG/VIAL | 11.9 MCG | POWDER FOR SOLUTION | PFIZER CANADA ULC | CANCELLED POST MARKET | 02215179 |
| MUSE | 1000 MCG | SUPPOSITORY | ENDO OPERATIONS LTD. | CANCELLED POST MARKET | 02238595 |
| MUSE | 250 MCG | SUPPOSITORY | ENDO OPERATIONS LTD. | CANCELLED POST MARKET | 02238593 |
| MUSE | 125 MCG | SUPPOSITORY | PALADIN PHARMA INC. | CANCELLED PRE MARKET | 02238592 |
| MUSE | 500 MCG | SUPPOSITORY | ENDO OPERATIONS LTD. | CANCELLED POST MARKET | 02238594 |
| VITAROS | 220 MCG / 100 MG | CREAM | BGP PHARMA ULC | APPROVED | 02359413 |
| VITAROS | 330 MCG / 100 MG | CREAM | BGP PHARMA ULC | APPROVED | 02359421 |
2 · Same class — other molecules in ATC G04BE
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Tadalafil | ACH-TADALAFIL · ACT TADALAFIL · ADCIRCA · AG-TADALAFIL · +21 more | 104 | 67 | Yes |
| Sildenafil | ACCEL-SILDENAFIL · ACT SILDENAFIL · AG-SILDENAFIL · AG-SILDENAFIL TABLETS · +30 more | 127 | 42 | Yes |
| Vardenafil | AG-VARDENAFIL · APO-VARDENAFIL · JAMP-VARDENAFIL · JAMP-VARDENAFIL ODT · +4 more | 19 | 12 | Yes |
| Alprostadil | CAVERJECT STERILE POWDER · CAVERJECT STERILE POWDER - KIT 11.9MCG /VIAL · CAVERJECT STERILE POWDER - PWS 11.9MCG/VIAL · CAVERJECT STERILE POWDER - PWS 23.2MCG/VIAL · +2 more | 10 | 2 | Yes |
| Yohimbin | YOCON TABLET 5.4MG · YOHIMBINE HCL 2MG · YOHIMBINE HCL 5.4MG · YOHIMBINE HYDROCHLORIDE TAB 2MG · +5 more | 9 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC G04B
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| G04BD | Darifenacin · Fesoterodine · Flavoxate · Oxybutynin · Propiverine · +4 more | 132 | 61 |
| G04BX | Dimethyl Sulfoxide · Phenazopyridine | 8 | 1 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is CAVERJECT STERILE POWDER called?
Also recorded in Canada as: alprostadil 0.02 MG Injection [Caverject] (US), 1 ML alprostadil 0.5 MG/ML Injection [Prostin VR] (US), 1 ML alprostadil 0.01 MG/ML Cartridge [Edex] (US), 1 ML alprostadil 0.02 MG/ML Cartridge [Edex] (US), 1 ML alprostadil 0.04 MG/ML Cartridge [Edex] (US), alprostadil 0.04 MG Injection [Caverject] (US), 0.5 ML alprostadil 0.02 MG/ML Prefilled Syringe [Caverject] (US), 0.5 ML alprostadil 0.04 MG/ML Prefilled Syringe [Caverject] (US), alprostadil 1 MG Urethral Suppository [Muse] (US), alprostadil 0.25 MG Urethral Suppository [Muse] (US), alprostadil 0.5 MG Urethral Suppository [Muse] (US), 1 ML alprostadil 0.01 MG/ML Cartridge (US), 1 ML alprostadil 0.02 MG/ML Cartridge (US), 1 ML alprostadil 0.04 MG/ML Cartridge (US), alprostadil 0.005 MG Injection (US).
The same molecule, Alprostadil, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Bondil | Latin | Norway |
| CAVERJECT | Latin | Brazil, Morocco |
| Caverject Impulse | Latin | Australia |
| Prostin VR | Latin | Bahrain, South Africa |
| Prostivas | Latin | Iceland, Norway |
| Vitaros | Latin | Norway |
| Alprostan | Latin | Slovakia |
| Prostavasin | Latin | Slovakia |
| PROSTIN VR AMP | Latin | Saudi Arabia |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.